State Street’s IGC Pharma IGC Stock Holding History

State Street’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.6K	Hold	200,799	–	–	﹤0.01%	4045
2026 Q1	$52.8K	Hold	200,799	–	–	﹤0.01%	4122
2025 Q4	$56.5K	Buy	200,799 +40,592	+25%	+$14.5K	﹤0.01%	4132
2025 Q3	$66.8K	Hold	160,207	–	–	﹤0.01%	4115
2025 Q2	$49K	Sell	160,207 -5,100	-3%	-$1.53K	﹤0.01%	4099
2025 Q1	$47.1K	Hold	165,307	–	–	﹤0.01%	4104
2024 Q4	$55.5K	Hold	165,307	–	–	﹤0.01%	4093
2024 Q3	$70.6K	Hold	165,307	–	–	﹤0.01%	4046
2024 Q2	$71.7K	Buy	165,307 +45,600	+38%	+$22.7K	﹤0.01%	4082
2024 Q1	$47.9K	Sell	119,707 -64,400	-35%	-$20K	﹤0.01%	4171
2023 Q4	$51.6K	Hold	184,107	–	–	﹤0.01%	4192
2023 Q3	$66.2K	Hold	184,107	–	–	﹤0.01%	4213
2023 Q2	$57.4K	Hold	184,107	–	–	﹤0.01%	4385
2023 Q1	$62.5K	Hold	184,107	–	–	﹤0.01%	4448
2022 Q4	$58.6K	Hold	184,107	–	–	﹤0.01%	4522
2022 Q3	$79K	Hold	184,107	–	–	﹤0.01%	4541
2022 Q2	$98K	Buy	184,107 +5,400	+3%	+$3.41K	﹤0.01%	4546
2022 Q1	$170K	Buy	178,707 +8,929	+5%	+$8.67K	﹤0.01%	4444
2021 Q4	$166K	Hold	169,778	–	–	﹤0.01%	4420
2021 Q3	$251K	Sell	169,778 -47,100	-22%	-$76.1K	﹤0.01%	4274
2021 Q2	$356K	Buy	+216,878	New	+$331K	﹤0.01%	3983

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street's IGC Position: Q2 2026 in Review

State Street held its IGC Pharma (IGC) position steady in Q2 2026 at 200,799 shares worth $54.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4045.

State Street first reported a position in IGC in Q2 2021 and has held it in 21 quarters since. The position peaked at $356K in Q2 2021. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

State Street held 200,799 shares of IGC Pharma worth $54.6K as of Q2 2026.
State Street left its IGC Pharma share count unchanged in Q2 2026.
IGC Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4045 holding.
State Street first reported a position in IGC Pharma in Q2 2021 and has held it in 21 quarters since.
State Street's IGC Pharma position peaked at $356K in Q2 2021.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.